MedTrace Logo

ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

NCT03334240 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-03-20

No results posted yet for this study

Summary

This study is intended to explore and evaluate the pharmacodynamics and clinical efficacy of the ionic contra-viral therapy CLS003 in immunocompromised and immunocompetent patients with benign and premalignant HPV-induced genital lesions

Conditions

  • HPV-Induced Genital Lesions

Interventions

DRUG

CLS003

CLS003

DRUG

Vehicle

Vehicle

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • J. (Koos) Burggraaf, MD, PhD · Centre For Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-05
Primary Completion
2018-10-30
Completion
2018-10-30
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03334240 on ClinicalTrials.gov